Citadel Advisors’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Citadel Advisors’s Portfolio BIOR Stock Details BIOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-139	Closed	-$4.9K	–	15781
2023 Q1	$3.84K	Sell	139 -508	-79%	-$17.2K	﹤0.01%	14002
2022 Q4	$21.3K	Buy	647 +508	+365%	+$37K	﹤0.01%	13097
2022 Q3	$17K	Buy	139 +92	+196%	+$16.6K	﹤0.01%	12141
2022 Q2	$8K	Sell	47 -1,641	-97%	-$346K	﹤0.01%	12640
2022 Q1	$489K	Buy	1,688 +496	+42%	+$188K	﹤0.01%	9455
2021 Q4	$623K	Buy	+1,192	New	+$855K	﹤0.01%	9131
2021 Q2	–	Sell	-152	Closed	-$116K	–	14741
2021 Q1	$181K	Buy	+152	New	+$210K	﹤0.01%	11822
2020 Q3	–	Sell	-400	Closed	-$900K	–	10986
2020 Q2	$900K	Buy	+400	New	+$1.09M	﹤0.01%	6021

Citadel Advisors's BIOR Position: Q2 2023 in Review

Citadel Advisors sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2023, closing a stake of 139 shares — an estimated $4.9K sold.

Citadel Advisors first reported a position in BIOR in Q2 2020 and held it in 8 quarters. The position peaked at $900K in Q2 2020. 30 funds tracked by Wall St. Rank hold BIOR as of Q2 2023.

Citadel Advisors reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 139 Biora Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.9K.
Citadel Advisors first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Citadel Advisors's Biora Therapeutics, Inc. Common Stock position peaked at $900K in Q2 2020.
30 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.